First-line nab-paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Results of the NEPTUN study

被引：3

作者：

Dechow, Tobias ^{[1
]}

Riera-Knorrenschild, Jorge ^{[2
]}

Hackanson, Bjoern ^{[3
]}

Janssen, Jan ^{[4
]}

Schulz, Holger ^{[5
]}

Chiabudini, Marco ^{[6
]}

Fischer von Weikersthal, Ludwig ^{[7
]}

Budweiser, Stephan ^{[8
]}

Nacke, Axel ^{[9
]}

Taeuscher, Dagmar ^{[10
]}

Welslau, Manfred ^{[11
]}

Potthoff, Karin ^{[12
]}

机构：

[1] Practice Oncol Ravensburg, Elisabethenstr 19, D-88212 Ravensburg, Germany

[2] Univ Hosp Giessen & Marburg GmbH, Marburg, Germany

[3] Univ Med Ctr Augsburg, Augsburg, Germany

[4] Practice Hematol & Oncol, Westerstede, Germany

[5] Practice Internal Oncol & Hematol, Frechen, Germany

[6] iOMEDICO, Dept Biostat, Freiburg, Germany

[7] Hlth Ctr St Marien GmbH, Amberg, Germany

[8] Hosp Rosenheim, Rosenheim, Germany

[9] Practice Hematol & Oncol, Remagen, Germany

[10] SRH Wald Klinikum Gera GmbH, Gera, Germany

[11] Hosp Aschaffenburg GmbH, Med Care Ctr, Aschaffenburg, Germany

[12] iOMEDICO, Dept Med, Freiburg, Germany

来源：

CANCER MEDICINE | 2021年 / 10卷 / 22期

关键词：

carboplatin; Germany; nab-paclitaxel; non-small cell lung carcinoma (NSCLC); real-world; THERAPY; COMBINATION;

D O I：

10.1002/cam4.4310

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Platinum-based chemotherapy remains a first-line standard of care for approximately 30% of patients with non-small cell lung cancer (NSCLC) not harboring a druggable alteration. Favorable efficacy and safety of the nab-paclitaxel/carboplatin (nab-P/C) combination was shown in the pivotal phase 3 trial. However, information on effectiveness of nab-P/C in a real-world setting in Germany is missing. The NEPTUN study prospectively investigated the effectiveness and safety of nab-P/C in patients with advanced NSCLC in a real-world setting. Methods Patients with advanced or metastatic NSCLC received first-line nab-P/C according to clinical routine. The primary endpoint was 6-month progression-free survival rate (PFS6). Other endpoints included further effectiveness parameters, safety and quality of life. Data were analyzed descriptively. Results 408 patients were enrolled. PFS6 was 40.8% (95% confidence interval [CI], 35.3-46.2); median PFS was 5.2 months (95% CI, 4.5-5.7). overall response rate was 41.5% (95% CI, 36.3-46.8). Median overall survival (OS) was 10.5 months (95% CI, 9.2-11.6). Subgroup analyses revealed median OS for squamous versus non-squamous histology (11.8 months [95% CI, 9.2-13.8] vs. 9.6 months [95% CI, 7.7-11.2]) and age >= 70 versus <70 years (11.7 months [95% CI, 9.4-14.3] vs. 9.6 months [95% CI, 7.5-11.2]). Most common treatment-emergent adverse events (TEAEs) were anemia (26.5%), leukopenia (25.7%), and thrombocytopenia (16.6%). Mostly reported grade 3/4 TEAEs were leukopenia (10.2%), anemia (8.6%), and pneumonia (5.1%). nab-paclitaxel-related deaths as reported by the investigator occurred in 0.8% of patients. Conclusion These real-world data support the effectiveness and safety of nab-P/C as first-line treatment for patients with advanced NSCLC independent of tumor histology. The results are comparable with the pivotal phase 3 trial. No new safety signals emerged.

引用

页码：8127 / 8137

页数：11

共 24 条

[1] Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting [J].

Abernethy, Amy P. ;

Arunachalam, Ashwini ;

Burke, Thomas ;

McKay, Caroline ;

Cao, Xiting ;

Sorg, Rachael ;

Carbone, David P. .

PLOS ONE, 2017, 12 (06)

[2]

Ettinger DS., CLIN PRACTICE GUIDEL

[3] nab-Paclitaxel-Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2 [J].

Gajra, Ajeet ;

Karim, Nagla Abdel ;

Mulford, Deborah A. ;

Villaruz, Liza Cosca ;

Matrana, Marc Ryan ;

Ali, Haythem Y. ;

Santos, Edgardo S. ;

Berry, Tymara ;

Ong, Teng Jin ;

Sanford, Alexandra ;

Amiri, Katayoun ;

Spigel, David R. .

FRONTIERS IN ONCOLOGY, 2018, 8

[4]

Griesinger F, 2018, ANN ONCOL, V29

[5] Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update [J].

Hanna, Nasser ;

Johnson, David ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Giaccone, Giuseppe ;

Hesketh, Paul J. ;

Jaiyesimi, Ishmael ;

Leighl, Natasha B. ;

Riely, Gregory J. ;

Schiller, Joan H. ;

Schneider, Bryan J. ;

Smith, Thomas J. ;

Tashbar, Joan ;

Biermann, William A. ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (30) :3484-+

[6] Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update [J].

Hanna, Nasser H. ;

Schneider, Bryan J. ;

Temin, Sarah ;

Baker, Sherman, Jr. ;

Brahmer, Julie ;

Ellis, Peter M. ;

Gaspar, Laurie E. ;

Haddad, Rami Y. ;

Hesketh, Paul J. ;

Jain, Dharamvir ;

Jaiyesimi, Ishmael ;

Johnson, David H. ;

Leighl, Natasha B. ;

Phillips, Tanyanika ;

Riely, Gregory J. ;

Robinson, Andrew G. ;

Rosell, Rafael ;

Schiller, Joan H. ;

Singh, Navneet ;

Spigel, David R. ;

Stabler, Janis O. ;

Tashbar, Joan ;

Masters, Gregory .

JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (14) :1608-+

[7] Lung cancer: current therapies and new targeted treatments [J].

Hirsch, Fred R. ;

Scagliotti, Giorgio V. ;

Mulshine, James L. ;

Kwon, Regina ;

Curran, Walter J. ;

Wu, Yi-Long ;

Paz-Ares, Luis .

LANCET, 2017, 389 (10066) :299-311

[8] Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease [J].

Igawa, Satoshi ;

Nishinarita, Noriko ;

Takakura, Akira ;

Ozawa, Takahiro ;

Harada, Shinya ;

Kusuhara, Seiichiro ;

Niwa, Hideyuki ;

Hosotani, Shinji ;

Sone, Hideyuki ;

Nakahara, Yoshiro ;

Fukui, Tomoya ;

Mitsufuji, Hisashi ;

Yokoba, Masanori ;

Kubota, Masaru ;

Katagiri, Masato ;

Sasaki, Jiichiro ;

Naoki, Katsuhiko .

CANCER MANAGEMENT AND RESEARCH, 2018, 10 :7013-7019

[9] Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial [J].

Jotte, Robert ;

Cappuzzo, Federico ;

Vynnychenko, Ihor ;

Stroyakovskiy, Daniil ;

Rodriguez-Abreu, Delvys ;

Hussein, Maen ;

Soo, Ross ;

Conter, Henry J. ;

Kozuki, Toshiyuki ;

Huang, Kuan-Chieh ;

Graupner, Vilma ;

Sun, Shawn W. ;

Hoang, Tien ;

Jessop, Helen ;

McCleland, Mark ;

Ballinger, Marcus ;

Sandler, Alan ;

Socinski, Mark A. .

JOURNAL OF THORACIC ONCOLOGY, 2020, 15 (08) :1351-1360

[10] Phase II study of nab-paclitaxel plus carboplatin for patients with non-small-cell lung cancer and interstitial lung disease [J].

Kenmotsu, Hirotsugu ;

Yoh, Kiyotaka ;

Mori, Keita ;

Ono, Akira ;

Baba, Tomohisa ;

Fujiwara, Yutaka ;

Yamaguchi, Ou ;

Ko, Ryo ;

Okamoto, Hiroaki ;

Yamamoto, Nobuyuki ;

Ninomiya, Takashi ;

Ogura, Takashi ;

Kato, Terufumi .

CANCER SCIENCE, 2019, 110 (12) :3738-3745

← 1 2 3 →